These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3115638)

  • 1. The place of intravenous GHRH 1-40 studies in the therapy of growth hormone-deficient children with GHRH.
    Smith PJ; Brook CG
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):97-105. PubMed ID: 3115638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma immunoreactive GHRH and serum GH concentrations following pulsatile GHRH 1-40 administration in GH deficient children.
    Smith PJ; Pringle PJ; Brook CG; Schulster D; Rafferty B
    Clin Endocrinol (Oxf); 1987 Oct; 27(4):501-7. PubMed ID: 3124994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency.
    Low LC; Wang C; Cheung PT; Ho P; Lam KS; Young RT; Yeung CY; Ling N
    J Clin Endocrinol Metab; 1988 Mar; 66(3):611-7. PubMed ID: 3127420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.
    Ghigo E; Imperiale E; Boffano GM; Mazza E; Bellone J; Arvat E; Procopio M; Goffi S; Barreca A; Chiabotto P
    J Endocrinol Invest; 1990 Apr; 13(4):307-16. PubMed ID: 2115060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pulsatile administration of growth hormone (GH)-releasing hormone on short term linear growth in children with GH deficiency.
    Gelato MC; Ross JL; Malozowski S; Pescovitz OH; Skerda M; Cassorla F; Loriaux DL; Merriam GR
    J Clin Endocrinol Metab; 1985 Sep; 61(3):444-50. PubMed ID: 3926806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nocturnal pulsatile growth hormone releasing hormone treatment in growth hormone deficiency.
    Smith PJ; Brook CG; Rivier J; Vale W; Thorner MO
    Clin Endocrinol (Oxf); 1986 Jul; 25(1):35-44. PubMed ID: 3098459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous growth hormone-releasing hormone augments pulsatile nocturnal GH release in GH-insufficient children, but may also raise basal GH secretion.
    Ross RJ; Kirk JM; Tsagarakis S; Trainer PJ; Ciccarelli E; Touzel R; Grossman A; Savage MO; Besser GM
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):239-48. PubMed ID: 2225481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity.
    Kirk JM; Trainer PJ; Majrowski WH; Murphy J; Savage MO; Besser GM
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):487-93. PubMed ID: 7955460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.
    Pihoker C; Middleton R; Reynolds GA; Bowers CY; Badger TM
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2987-92. PubMed ID: 7559885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained improvement in growth velocity and recovery from suboptimal growth hormone (GH) secretion after treatment with human pituitary GH-releasing hormone-(1-44)-NH2.
    Lifshitz F; Lanes R; Pugliese M; Fort P; Perez I; Puentes S; Cervantes C; Gunczler P; Chasalow FI; Recker B
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1255-60. PubMed ID: 1430086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte subset distribution and natural killer activity in growth hormone deficiency before and during short-term treatment with growth hormone releasing hormone.
    Kiess W; Malozowski S; Gelato M; Butenand O; Doerr H; Crisp B; Eisl E; Maluish A; Belohradsky BH
    Clin Immunol Immunopathol; 1988 Jul; 48(1):85-94. PubMed ID: 3133146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of acute and chronic growth hormone (GH) administration on GH secretion in patients with idiopathic GH deficiency.
    Hanew K; Goh M; Sato S; Shimizu Y; Sasaki A; Aida M; Yoshinaga K
    J Clin Endocrinol Metab; 1988 Apr; 66(4):715-21. PubMed ID: 3126213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.
    Vance ML; Kaiser DL; Martha PM; Furlanetto R; Rivier J; Vale W; Thorner MO
    J Clin Endocrinol Metab; 1989 Jan; 68(1):22-8. PubMed ID: 2491864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of beta 1-adrenergic blockade on the growth response to growth hormone (GH)-releasing hormone therapy in GH-deficient children.
    Cassorla F; Mericq V; García H; Cristiano A; Avila A; Boric A; Iñiguez G; Merriam GR
    J Clin Endocrinol Metab; 1995 Oct; 80(10):2997-3001. PubMed ID: 7559887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of 24-hour growth hormone secretion after continuous subcutaneous infusion of growth hormone-releasing hormone (GHRH (1-29)NH2) in short children with low 24-hour growth hormone secretion.
    Tauber MT; Pienkowski C; Landier F; Gunnarsson R; Rochiccioli P
    Acta Paediatr Scand Suppl; 1989; 349():117-22; discussion 123-4. PubMed ID: 2546370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone-releasing hormone in the diagnosis and treatment of growth hormone deficient children.
    Ross RJ; Grossman A; Besser GM; Savage MO
    Acta Endocrinol Suppl (Copenh); 1986; 279():123-9. PubMed ID: 3096037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
    Pombo M; Barreiro J; Peñalva A; Peino R; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridostigmine fails to increase either spontaneous or GHRH-stimulated GH secretion during day or night in growth hormone-insufficient children.
    Kirk JM; Ross RJ; Trainer PJ; Froud AL; Davies SC; Savage MO; Besser GM
    Clin Endocrinol (Oxf); 1991 May; 34(5):407-11. PubMed ID: 2060150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of continuous subcutaneous growth hormone-releasing hormone (GHRH (1-29)NH2) infusions to augment growth hormone secretion and to promote growth.
    Brain C; Hindmarsh PC; Pringle PJ; Brook CG
    Acta Paediatr Scand Suppl; 1989; 349():109-13; discussion 123-4. PubMed ID: 2546369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of pulsatile administration, continuous infusion, and diurnal variation on the growth hormone (GH) response to GH-releasing hormone in normal men.
    Hulse JA; Rosenthal SM; Cuttler L; Kaplan SL; Grumbach MM
    J Clin Endocrinol Metab; 1986 Oct; 63(4):872-8. PubMed ID: 3091629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.